[转移性乳腺癌患者换用芬太尼透皮贴剂后口服吗啡和羟考酮所致不良事件影响减轻的一项前瞻性研究]

[A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer].

作者信息

Ikeda Masahiko, Sonoo Hiroshi, Kurebayashi Junichi, Oota Yusuke, Fujii Sayaka, Shimo Toshirou, Mizutou Akiko, Seki Mari, Saitou Wataru, Yamashita Tetsumasa, Koike Yoshikazu, Yamamoto Yutaka, Shiiki Shigeo, Nakashima Kazutaka, Tanaka Katsuhiro, Nomura Tsunehisa, Kubo Shinichirou

机构信息

Dept. of Breast and Thyroid Surgery, Fukuyama City Hospital.

出版信息

Gan To Kagaku Ryoho. 2012 Apr;39(4):599-603.

PMID:22504685

Abstract

BACKGROUND

It has been confirmed by several clinical trials that the fentanyl patch causes less adverse events than sustained-release oral morphine, and after rotation. However, there has been no evidence comparing the fentanyl patch with controlled-release oral oxycodone in terms of adverse events.

PURPOSE

We prospectively investigated the reduced effects of adverse events caused by sustained-release oral morphine and controlled-release oxycodone after rotating to the fentanyl patch in patients with metastatic breast cancer.

METHOD

Metastatic breast cancer patients requiring sustained-release oral morphine or controlled-release oral oxycodone(n=9, 2 taking oral morphine, 7 taking oral oxycodone, mean age, 57. 5 years)were recruited. Those experiencing adverse events from oral morphine or oral oxycodone were administered a fentanyl patch.

RESULTS

The pain score was reduced significantly at the 4th week. The fentanyl patch was associated with significantly less nausea, vomiting, constipation, sleepiness and dizziness over the study period.

CONCLUSION

This study suggested that the fentanyl patch can reduce adverse events caused by sustained-release oral morphine as well as controlled-release oral oxycodone.

摘要